English
Calliditas is focused on the development and commercialization of its lead product candidate Nefecon.
A potential treatment for patients with IgA nephropathy at risk of developing ESRD.
The Balancing Act, Lifetime TV’s morning program, aired a half-hour segment on IgA Nephropathy in the ‘Behind the Mystery’ program. An IgA patient and Leicester University’s Professor Jonathan Barratt discussed the disease and the challenges patients face due to lack of specifically developed treatments.
On May 18, 2021, at 07:00 CEST, Calliditas Therapeutics published its interim report for the first quarter 2021. A conference call will be held to present and discuss the results, at 2.30 pm CEST.
